You are here: Industry Insights > luspatercept

News List

Luspatercept Mitigates Anemia in Lower-Risk Myelodysplastic Syndromes drugs
January 20, 2020
For patients with lower-risk myelodysplastic syndromes with ring sideroblasts who have been receiving regular red-cell transfusions, luspatercept reduces the severity of anemia compared with placebo ...
Celgene Corporation and Acceleron Pharma Announce U.S. FDA Accepts Luspatercept Biologics License Application in Myelodysplastic Syndromes and Beta-Thalassemia drugs
June 11, 2019
Celgene Corporation and Acceleron Pharma Announce U.S. FDA Accepts Luspatercept Biologics License Application in Myelodysplastic Syndromes and Beta-Thalassemia.
Celgene Corporation and Acceleron Pharma Announce Submission of Luspatercept Biologics License Application to U.S. FDA drugs
April 11, 2019
Celgene Corporation and Acceleron Pharma Announce Submission of Luspatercept Biologics License Application to U.S. FDA.
Celgene’s luspatercept aces phase 3 beta thalassemia trial fiercebiotech
January 03, 2019
A phase 3 trial of Celgene’s luspatercept in adults with beta thalassemia has hit its primary goal. The late-phase success tees Celgene to file for approval of its Acceleron-partnered blockbuster prospect in the first half of next year......
Celgene and Acceleron Announce Luspatercept Achieved Primary and All Key Secondary Endpoints in Phase III ‘BELIEVE’ Study in Adults with Transfusion-Dependent Beta-Thalassemia firstwordpharma
July 10, 2018
Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced results from a phase III, randomized, double-blind
Celgene, Acceleron to file MDS therapy in the EU, US pharmatimes
July 04, 2018
Celgene and Acceleron Pharma are preparing to file their experimental myelodysplastic syndromes (MDS) therapy on both sides of the Atlantic on the back of promising data from a late-stage study.